Table 3.
VEGF expression and survival in non-metastatic invasive breast cancer by adjuvant systemic therapy and expression of ER and PR
| Total | Breast cancer-specific mortality |
Distant recurrence |
Overall mortality |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | Death/ Person- years |
Univariate HR (95% CI) |
Multivariate HR (95% CI) |
Event/ Person- years |
Univariate HR (95% CI) |
Multivariate HR (95% CI) |
Death/ Person- years |
Univariate HR (95% CI) |
Multivariate HR (95% CI) |
|
| Patients untreated systemically | ||||||||||
| VEGF negative | 82 | 2/1365 | Reference | Reference | 4/1329 | Reference | Reference | 19/1365 | Reference | Reference |
| VEGF positive | 180 | 22/2877 | 5.49 (1.28, 23.45) |
5.58 (1.17, 26.66)a |
23/2831 | 2.70 (0.94, 7.82) |
1.88 (0.61, 5.78)a |
55/2877 | 1.40 (0.83, 2.36) |
1.36 (0.78, 2.38)a |
| P | 0.02 | 0.03 | 0.07 | 0.27 | 0.21 | 0.28 | ||||
| Patients with adjuvant hormonal therapy | ||||||||||
| VEGF negative | 253 | 30/3663 | Reference | Reference | 31/3581 | Reference | Reference | 73/3663 | Reference | Reference |
| VEGF positive | 649 | 97/9109 | 1.30 (0.87, 1.96) |
0.99 (0.65, 1.53)b |
102/8797 | 1.32 (0.89, 1.98) |
1.07 (0.70, 1.63)b |
207/9109 | 1.15 (0.88, 1.50) |
1.02 (0.77, 1.35)b |
| P | 0.21 | 0.97 | 0.17 | 0.76 | 0.32 | 0.91 | ||||
| Patients with both ER- and PR-positive tumors and adjuvant hormonal therapy | ||||||||||
| VEGF negative | 195 | 19/2804 | Reference | Reference | 20/2744 | Reference | Reference | 56/2804 | Reference | Reference |
| VEGF positive | 451 | 64/6408 | 1.48 (0.89, 2.47) |
1.08 (0.63, 1.86)c |
70/6177 | 1.56 (0.95, 2.56) |
1.22 (0.72, 2.05)c |
136/6408 | 1.06 (0.78, 1.45) |
0.94 (0.67, 1.31)c |
| P | 0.13 | 0.78 | 0.08 | 0.46 | 0.72 | 0.70 | ||||
Adjusted for age at diagnosis (continuous), body mass index at diagnosis (continuous), menopausal status at diagnosis (premenopausal, postmenopausal, or unknown), smoking status prior to diagnosis (never smoking, past smoking, current smoking, or unknown), year of diagnosis (continuous), tumor size (>2 or ≤2 cm), histological grade (I/II, III, or unknown), nodal status (positive or negative), and status of ER, PR, HER2, EGFR, and cytokeratin 5/6 (positive, negative, or unknown)
Adjusted for the above factors as well as adjuvant chemotherapy (yes, no, or unknown)
Adjusted for factors mentioned in b except for ER and PR status